{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T18:10:05Z","timestamp":1773079805854,"version":"3.50.1"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ribociclib, a cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitor, occupies a pivotal role in the clinical management of metastatic breast cancer, with its hematologic and gastrointestinal toxicities well-established. However, cutaneous adverse reactions induced by this agent\u2014among which vitiligo is particularly prominent\u2014are extremely rare. Herein, we report a case of vitiligo-like lesions induced by ribociclib, aiming to elucidate this underrecognized drug-adverse reaction association and conduct an in-depth analysis of its potential immune-mediated mechanism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case summary<\/jats:title>\n                    <jats:p>A 59-year-old woman with ER\/PR (90% strong+), HER2-negative metastatic breast cancer developed pruritic hypopigmented patches on her forearms 16 months after initiating ribociclib\/letrozole. Dermoscopy revealed complete pigment loss, peripheral hyperpigmentation, and telangiectasia. Wood\u2019s lamp examination demonstrated bright blue-white fluorescence, confirming non-segmental vitiligo. No personal\/family history of autoimmunity was noted. Topical 0.1% mometasone cream and 0.1% tacrolimus ointment were initiated, with stabilization of existing lesions and no new depigmentation at 2-month follow-up. Ribociclib was maintained due to ongoing tumor control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>HR-positive metastatic breast cancer patients using ribociclib may develop vitiligo, with individual differences (e.g., over one-year incubation as in this case). Combined with prior reports, it suggests a link between ribociclib and vitiligo. Further clinical observations and studies are needed to confirm causality, and pre-use risk explanations to patients are advisable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1669407","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T05:12:33Z","timestamp":1765170753000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Vitiligo associated with ribociclib therapy: a rare case report"],"prefix":"10.3389","volume":"15","author":[{"given":"Zirui","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]},{"name":"Health Science Center, Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanrui","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rihan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yihui","family":"Liu","sequence":"additional","affiliation":[{"name":"Radiotherapy Oncology, People\u2019s Hospital of Ningxia Hui Autonomous Region","place":["Yinchuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunhui","family":"Dong","sequence":"additional","affiliation":[{"name":"Cardiovascular Hospital, Ninth Hospital of Xi\u2019an","place":["Xi\u2019an, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e2013226","DOI":"10.1001\/jamanetworkopen.2020.13226","article-title":"Incidence trends of breast cancer molecular subtypes by age and race\/ethnicity in the US from 2010 to 2016","volume":"3","author":"Acheampong","year":"2020","journal-title":"JAMA Netw Open"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.0032","article-title":"Cell-cycle therapeutics come of age","volume":"35","author":"Ingham","year":"2017","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"R77","DOI":"10.1186\/bcr2419","article-title":"PD0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro","volume":"11","author":"Finn","year":"2009","journal-title":"Breast Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0443","article-title":"The role of CDK4\/6 inhibition in breast cancer","volume":"20","author":"Murphy","year":"2015","journal-title":"Oncologist"},{"key":"B5","doi-asserted-by":"publisher","first-page":"111580","DOI":"10.1016\/j.microc.2024.111580","article-title":"First voltammetric studies, spectrophotometric and molecular docking investigations of the interaction of an anticancer drug ribociclib-DNA and analytical applications of disposable pencil graphite sensor","volume":"206","author":"Aslan","year":"2024","journal-title":"Microchemical J"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy155","article-title":"Updated results from MONALEESA-2, a phase III trial of firstline ribociclib plus letrozole versus placebo plus letrozole in hormone receptor positive, HER2-negative advanced breast cancer","volume":"29","author":"Hortobagyi","year":"2018","journal-title":"Ann Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00144","article-title":"Final results of RIGHT choice: ribociclib plus endocrine therapy versus combination chemotherapy in premenopausal women with clinically aggressive hormone receptor\u2013positive\/human epidermal growth factor receptor 2\u2013negative advanced breast cancer","volume":"42","author":"Lu","year":"2024","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1177\/10781552251340613","article-title":"Rechallenge of an alternative CDK 4\/6 inhibitor after hepatotoxicity in the treatment of hormone-positive metastatic breast cancer","volume":"31","author":"Jackson","year":"2025","journal-title":"J Oncol Pharm Pract"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1177\/1060028018817904","article-title":"Ribociclib in HR+\/HER2\u2013 advanced or metastatic breast cancer patients","volume":"53","author":"Rascon","year":"2019","journal-title":"Ann Pharmacother"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae004","article-title":"Ribociclib-induced cutaneous adverse events in metastatic HR+\/HER2- breast cancer: incidence, multidisciplinary management, and prognostic implication","volume":"29","author":"Borroni","year":"2024","journal-title":"Oncologist"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3032","article-title":"Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+\/HER2- advanced breast cancer in MONALEESA-7: A Phase III randomized clinical trial","volume":"28","author":"Lu","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"115225","DOI":"10.1016\/j.ejca.2025.115225","article-title":"Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+\/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials","volume":"217","author":"Lu","year":"2025","journal-title":"Eur J Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf123","article-title":"Pre-existing and emerging immune-mediated diseases in patients with breast cancer undergoing cyclin-dependent kinases 4\/6 inhibitors and endocrine therapy","volume":"30","author":"Jacobs","year":"2025","journal-title":"Oncologist"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e2022045","DOI":"10.5826\/dpc.1202a45","article-title":"Ribociclib-induced vitiligo: a case report","volume":"12","author":"Torner","year":"2022","journal-title":"Dermatol Pract Concept"},{"key":"B17","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3390\/diseases13050158","article-title":"A vitiligo-like cutaneous reaction induced by ribociclib in advanced breast cancer: an unusual case report from Colombia","volume":"13","author":"Montenegro","year":"2025","journal-title":"Diseases"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1159\/000506103","article-title":"Vitiligo: A review","volume":"236","author":"Bergqvist","year":"2020","journal-title":"Dermatology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32020","article-title":"Molecular mechanisms of resistance to CDK4\/6 inhibitors in breast cancer: A review","volume":"145","author":"Pandey","year":"2019","journal-title":"Int J Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0915","article-title":"CDK4\/6 inhibition augments anti-tumor immunity by enhancing T cell activation","volume":"8","author":"Deng","year":"2018","journal-title":"Cancer Discov"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1197630","article-title":"Insight into immune profile associated with vitiligo onset and anti-tumoral response in melanoma patients receiving anti-PD-1 immunotherapy","volume":"14","author":"Carbone","year":"2023","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.83513","article-title":"Vitiligo-like depigmentation induced by cyclin-dependent kinase 4\/6 inhibitors in the treatment of metastatic breast cancer: a case report and literature review","volume":"17","author":"Lee","year":"2025","journal-title":"Cureus"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13585","article-title":"Drug induced vitiligo-like depigmentation from a CDK 4\/6 inhibitor","volume":"18","author":"Chan","year":"2021","journal-title":"Asia-Pac J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e57677","DOI":"10.7759\/cureus.57677","article-title":"Abemaciclib-associated skin, hair, and nail toxicities: A case report","volume":"16","author":"Alsatti","year":"2024","journal-title":"Cureus"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1611115","DOI":"10.3389\/pore.2023.1611115","article-title":"Vitiligo-like lesions induced by cyclin-dependent kinase 4\/6 inhibitor Palbociclib: a case report and literature review","volume":"29","author":"Gao","year":"2023","journal-title":"Pathol Oncol Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1177\/10781552231156521","article-title":"Vitiligo-like lesions associated with ribociclib in a woman with metastatic breast cancer","volume":"9","author":"T\u00fcrkel","year":"2023","journal-title":"J Oncol Pharm Pract"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2022-248782","article-title":"Ribociclib- induced extensive vitiligo- like lesions: possible pathomechanisms with clinical, dermoscopic and histological correlation","volume":"15","author":"Anjaneyan","year":"2022","journal-title":"BMJ Case Rep"},{"key":"B28","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2147\/CCID.S344867","article-title":"Vitiligo-like lesions in a patient with metastatic breast cancer treated with cyclin-dependent kinase (CDK) 4\/6 inhibitor: A case report and literature review","volume":"15","author":"Sharaf","year":"2022","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2022.11.013","article-title":"Dermatologic toxicities to inhibitors of cyclin-dependent kinases CDK 4 and 6: An updated review for clinical practice","volume":"150","author":"Sibaud","year":"2023","journal-title":"Annales Dermatologie V\u00e9n\u00e9r\u00e9ologie. Ann Dermatol Venereol"}],"updated-by":[{"DOI":"10.3389\/fonc.2026.1790586","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000}}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1669407\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T14:44:59Z","timestamp":1769438699000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1669407\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":29,"alternative-id":["10.3389\/fonc.2025.1669407"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1669407","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"article-number":"1669407"}}